Frankly, I don't think anyone on this panel has sufficient expertise to really judge, advise or suggest the types of changes, improvements, studies, etc., that might be relevant in this area.
If that is indeed the case, then I think all they can do for the key question is vote on whether the numbers stack up as to mortality and improvement in patients with srAGVHD.
Frankly, I don't think anyone on this panel has sufficient...
-
- There are more pages in this discussion • 1,332 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.46 |
Change
0.065(4.66%) |
Mkt cap ! $1.684B | |||
| Open | High | Low | Value | Volume |
| $1.41 | $1.50 | $1.40 | $5.699M | 3.943M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 122692 | $1.46 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 11015 | 2 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |